Press Release

February 23, 2021
1 min read

FDA grants fast track designation to GEN-1 for advanced ovarian cancer


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent’s manufacturer.

GEN-1 (Celsion) is a DNA-mediated interleukin-12 immunotherapy.

3d illustration of ovarian cancer
Source: Adobe Stock.

“Fast track designation is an important step in developing GEN-1 for advanced ovarian cancer,” Michael H. Tardugno, Celsion’s chairman, president and CEO, said in a company-issued press release. “Presuming the encouraging data we are generating in early clinical studies continues, this designation supports an expedited path to market. ... We are optimistic that GEN-1 represents a game-changer for women with advanced ovarian cancer who have limited treatment options.”

The phase 2 OVATION 2 study is evaluating the addition of GEN-1 to standard neoadjuvant chemotherapy for women with newly diagnosed stage III/stage IV ovarian cancer. PFS serves as the primary endpoint.

Results of the phase 1 portion of the trial showed a higher rate of complete tumor resection among women assigned GEN-1 plus neoadjuvant chemotherapy than those assigned chemotherapy alone (88% vs. 50%).